The DEK Oncogene Activates VEGF Expression and Promotes Tumor Angiogenesis and Growth in HIF-1α-dependent and -Independent Manners.

Yanan Zhang,Jie Liu,Shibin Wang,Xiaoli Luo,Yang Li,Zhaohui Lv,Jie Zhu,Jing Lin,Lihua Ding,Qinong Ye

DOI: https://doi.org/10.18632/oncotarget.8060

2016-01-01

Oncotarget

Abstract:The DEK oncogene is overexpressed in various cancers and overexpression of DEK correlates with poor clinical outcome. Vascular endothelial growth factor (VEGF) is the most important regulator of tumor angiogenesis, a process essential for tumor growth and metastasis. However, whether DEK enhances tumor angiogenesis remains unclear. Here, we show that DEK is a key regulator of VEGF expression and tumor angiogenesis. Using chromatin immunoprecipitation assay, we found that DEK promoted VEGF transcription in breast cancer cells (MCF7, ZR75-1 and MDA-MB-231) by directly binding to putative DEK-responsive element (DRE) of the VEGF promoter and indirectly binding to hypoxia response element (HRE) upstream of the DRE through its interaction with the transcription factor hypoxia-inducible factor 1a (HIF-1a), a master regulator of tumor angiogenesis and growth. DEK is responsible for recruitment of HIF-1a and the histone acetyltransferase p300 to the VEGF promoter. DEK-enhanced VEGF increases vascular endothelial cell proliferation, migration and tube formation as well as angiogenesis in the chick chorioallantoic membrane. DEK promotes tumor angiogenesis and growth in nude mice in HIF-1a-dependent and -independent manners. Immunohistochemical staining showed that DEK expression positively correlates with the expression of VEGF and microvessel number in 58 breast cancer patients. Our data establish DEK as a sequence-specific binding transcription factor, a novel coactivator for HIF-1a in regulation of VEGF transcription and a novel promoter of angiogenesis.